ASX ANNOUNCEMENT
30 June 2025

SECONDARY TRADING NOTICE PURSUANT TO SECTION 708A(5) OF THE CORPORATIONS ACT 2001 ("Act")

On 27 June 2025, Biome Australia Limited ("**the Company**") (ASX:BIO) issued a total of 1,286,926 fully paid ordinary shares ("**Shares**") in the capital of the Company. The Shares were issued under the Company's Employee Incentive Plan and to advisors in lieu of advisory services.

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the on sale of the Shares noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

(a) The Company issued a total of 1,286,926 Shares on 27 June 2025 without disclosure to investors under Part 6D.2 of the Act.
(b) The Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
(c) There is no information:
  (i) That has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  (ii) That investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    A. The assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    B. The rights and liabilities attaching to the Shares.

The relevant Appendix 2A's were lodged via ASX on-line forms.

-Ends-

Authorised by the Board.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics.

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations
Rechelle Friend
+61 (3) 9017 5800
corporate@biomeaustralia.com

Media enquiries
media@activated.co